Heterocyclic compounds as RET kinase inhibitors
The present invention relates to compounds of formula I that function as inhibitors of RET (rearranged during transfection) kinase enzyme activity: wherein HET, X1, X2, X3, X4, integer a and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which RET kinase activity is implicated..
Medienart: |
Patent |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Europäisches Patentamt - (2023) vom: 30. Mai Zur Gesamtaufnahme - year:2023 |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
JORDAN ALLAN MICHAEL [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
Sonstige Themen: |
---|
Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-05-30, Last update posted on www.tib.eu: 2023-10-11, Last updated: 2023-10-20 |
---|
Patentnummer: |
US11661423 |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
EPA017548101 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | EPA017548101 | ||
003 | DE-627 | ||
005 | 20231020095732.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230708s2023 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)EPA017548101 | ||
035 | |a (EPA)US11661423 | ||
035 | |a (EPA)58633036 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 0 | |a JORDAN ALLAN MICHAEL |e verfasserin |4 aut | |
245 | 1 | 0 | |a Heterocyclic compounds as RET kinase inhibitors |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: www.epo.org (no modifications made), First posted: 2023-05-30, Last update posted on www.tib.eu: 2023-10-11, Last updated: 2023-10-20 | ||
520 | |a The present invention relates to compounds of formula I that function as inhibitors of RET (rearranged during transfection) kinase enzyme activity: wherein HET, X1, X2, X3, X4, integer a and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which RET kinase activity is implicated. | ||
650 | 4 | |a C07D: Heterocyclic compounds (macromolecular compounds c08) | |
650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
650 | 4 | |a che | |
650 | 4 | |a 615 | |
700 | 0 | |a NEWTON REBECCA |4 aut | |
700 | 0 | |a WASZKOWYCZ BOHDAN |4 aut | |
700 | 0 | |a SUTTON JONATHAN MARK |4 aut | |
700 | 0 | |a HYND GEORGE |4 aut | |
700 | 0 | |a PAOLETTA SILVIA |4 aut | |
700 | 0 | |a FORDYCE EUAN ALEXANDER FRASER |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 30. Mai |
773 | 1 | 8 | |g year:2023 |g day:30 |g month:05 |
856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/58633036/publication/US11661423A1?q=US11661423 |z kostenfrei |3 Volltext |
912 | |a GBV_EPA | ||
936 | u | w | |j 2023 |b 30 |c 05 |
951 | |a AR | ||
952 | |j 2023 |b 30 |c 05 |